Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIa Randomized, Partially Blinded Trial of Telaprevir (VX-950) in Treatment-Naive Subjects With Chronic Genotype 4 Hepatitis C Infection
Brief Summary: The purpose of this study is to evaluate the activity and safety of telaprevir on Hepatitis C Virus (HCV) Genotype 4, alone or in combination with standard therapy, that is, pegylated-interferon-alfa-2a and ribavirin in treatment-naive (never been treated before with antiretroviral therapy) participants.


Options:
A: Arm Label: Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated-interferon-alfa-2a, Drug: Ribavirin | Arm Label: Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated-interferon-alfa-2a, Drug: Ribavirin | Arm Label: Placebo+Pegylated-interferon-alfa-2a+Ribavirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated-interferon-alfa-2a, Drug: Placebo, Drug: Ribavirin | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Pegylated-interferon-alfa-2a; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin
B: Arm Label: PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV | Arm Label: BI 201335 for 12 or 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: BI 201335 | Arm Label: Placebo and PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV, Drug: Placebo | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 for 12 or 24 weeks, PegIFN/RBV, Placebo and PegIFN/RBV | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and PegIFN/RBV
C: Arm Label: Treatment A: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment B: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment C: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment D: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment E: PSI-7977 + Daclatasvir + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment F: PSI-7977 + Daclatasvir+ Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment G: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment H: PSI-7977 + BMS-790052 + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Arm Label: Treatment I: PSI-7977 + Daclatasvir; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir | Arm Label: Treatment J: PSI-7977 + Daclatasvir + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: PSI-7977, Drug: Daclatasvir, Drug: Ribavirin | Intervention Type: DRUG; Name: PSI-7977; Assigned to Arm(s): Treatment A: PSI-7977 + Daclatasvir, Treatment B: PSI-7977 + Daclatasvir, Treatment C: PSI-7977 + Daclatasvir, Treatment D: PSI-7977 + Daclatasvir, Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment G: PSI-7977 + Daclatasvir, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment I: PSI-7977 + Daclatasvir, Treatment J: PSI-7977 + Daclatasvir + Ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Treatment A: PSI-7977 + Daclatasvir, Treatment B: PSI-7977 + Daclatasvir, Treatment C: PSI-7977 + Daclatasvir, Treatment D: PSI-7977 + Daclatasvir, Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment G: PSI-7977 + Daclatasvir, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment I: PSI-7977 + Daclatasvir, Treatment J: PSI-7977 + Daclatasvir + Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Treatment E: PSI-7977 + Daclatasvir + Ribavirin, Treatment F: PSI-7977 + Daclatasvir+ Ribavirin, Treatment H: PSI-7977 + BMS-790052 + Ribavirin, Treatment J: PSI-7977 + Daclatasvir + Ribavirin
D: Arm Label: Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (B); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (C); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Placebo, Peginterferon alpha-2a, ribavirin (D); Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a, Drug: ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (C) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: Peginterferon alpha-2a; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D)

Answer: A